This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Data Unnerve DepoMed Investors

DepoMed (DEPO - Get Report) shares nosedived Tuesday after the specialty pharmaceutical company announced that a phase III clinical trial for Gabapentin didn't meet its primary endpoint.

The Menlo Park, Calif., company's investigational extended release tablet was intended for treatment of neuropathic pain, specifically patients with postherpetic neuralgia, or a persistent pain due to nerve damage after shingles or herpes zoster infection. But Gabapentin GR, given in a 1800-mg dose once or twice a day over a 10-week period, didn't show statistically significant efficacy compared to the placebo.

"The phase III results we received today were very surprising and disappointing to us in light of the encouraging safety and efficacy data that we observed in our phase II clinical trial, in which we achieved statistically significant results in a four-week period as compared to placebo," said DepoMed CEO John Fara.

DepoMed said statistical significance relative to placebo was achieved in each of the first six weeks for the once-daily treatment arm of the study and in each of the first five weeks for the twice-daily treatment arm, but that pain scores in the placebo group continued to improve in the last four weeks of the study.

"We saw clinically meaningful and statistically significant reductions in pain scores from baseline to the 10-week endpoint in both active treatment arms," Fara said. "However, the unexpected improvements in the pain scores of the placebo group during the last four weeks of the study prevented the achievement of statistical significance in the primary endpoint that is required by the FDA."

DepoMed said that it will evaluate the results further to decide how to proceed. Its stock was recently sinking $2.87, or 58%, to $2.06.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
DEPO $20.45 0.00%
AAPL $124.53 0.00%
FB $85.80 0.00%
GOOG $521.52 0.00%
TSLA $262.02 0.00%

Markets

DOW 17,596.35 -350.33 -1.95%
S&P 500 2,057.64 -43.85 -2.09%
NASDAQ 4,958.4680 -122.0370 -2.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs